Llwytho...
Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patients
The HER2/neu (ERBB2) oncogene is amplified and/or overexpressed in approximately 20% of breast cancers, and is a strong prognostic factor for relapse and poor overall survival, particularly in node-positive patients. It is also an important predictor for response to trastuzumab, which has establishe...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Contemp Oncol (Pozn) |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Termedia Publishing House
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4829743/ https://ncbi.nlm.nih.gov/pubmed/27095932 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/wo.2016.58495 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|